Charting the Course of the AI Revolution in Biomedicine Keystone Symposia charts the evolution of AI in biomedicine, from theory to application, shaping the future of life science research.

Discover insights from the tranformative #AIinMolecularBiology meeting (now On Demand) & look ahead to what’s next in the rapidly evolving #AIinDrugDiscovery field at the KS on Computational Advances in Drug Discovery in May, London- also Livestreamed! keypoint.keystonesymposia.org/home/chartin...

Servier signs €1bn-plus AI pact with Iktos In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.

#drugdiscovery #Servier #Iktos #Chemspeed #roboticspoweredchemistryplatform #smallmoleculetherapies #generativeAI #PharmaAIdrugdiscoveryplatform #smallmoleculedrugdiscovery #AIorchestrateddiscovery
#translationalscience #smallmoleculetherapeutics #AIindrugdiscovery #RandD
zurl.co/L8opQ

Happy Holidays from BioSymetrics and Lunai Bioworks

We tried something silly: we asked AI to adapt the lyrics of a familiar seasonal tune as a playful ode to zebrafish behavior analysis. Check out this post's image for the lyrics. #DrugDiscovery #Biodefense #AIinDrugDiscovery

HTS-Oracle: Experimentally validated AI-enabled prioritization for generalizable small molecule hit discovery
Calvo-Barreiro, L. et al.
Paper
Details
#AIinDrugDiscovery #MoleculeHitPrioritization #HTSOracle

"Digital twins and drugs" 💊

Listen to the full #ProteintechPodcast episode with Dr. Layla Hosseini-Gerami here: linktr.ee/proteintechp...

#drugsafety #AIindrugdiscovery

LinkedIn This link will take you to a page that’s not on LinkedIn

🎧 New Target 2035 Podcast!

Rachel Harding & Matthieu Schapira dive into #CACHEChallenges — a global effort to refine small-molecule discovery algorithms with real-world validation.

🔬 How does CACHE boost #DrugDiscovery? Find out: lnkd.in/gcwkUXup

#AIinDrugDiscovery #OpenScience #MachineLearning

Hyper-C, our proprietary AI platform, harnesses the power of big data to create molecular models that match compounds to diseases with unprecedented accuracy. 🧬💡

Get more details here!
https://buff.ly/4jTamyT

#Delta4 #AIInDrugDiscovery #Hyper-C

Have you explored this approach in your research? Let’s discuss!

#Cheminformatics #MachineLearning #ConformalPrediction #AIinDrugDiscovery #DataScience #PharmaceuticalResearch

Our AI-driven Hyper-C platform accelerates drug discovery by identifying new indications for existing compounds. Our computational biologists provide precise insights, enabling faster, cost-effective therapeutic development.
#Delta4 #AIInDrugDiscovery #LifeSciencesInnovation

Shicheng Guo on LinkedIn: 💭 Excited to discuss AI’s role in precision medicine? I’m looking forward… 💭 Excited to discuss AI’s role in precision medicine? I’m looking forward to leading an insightful roundtable discussion on how AI is reshaping target…

Excited to lead a roundtable at AI in Drug Discovery– San Diego! 🚀

📅 Feb 24, 2025 | ⏰ 09:05-10:05 AM

📍 Target ID Track

Discussing AI in multi-omics, biomarker discovery & explainable AI. Let’s connect!

#AIinDrugDiscovery #PrecisionMedicine

www.linkedin.com/posts/shg047...

💡We mapped identified PTMs to structural domains in the ECOD database and report all data at DrugDomain database (prodata.swmed.edu/DrugDomain/), which offers the first large-scale collection of PTM-modified protein models with docked small molecules.
#AIinDrugDiscovery #ProteinBinding #AlphaFold

A good discussion on potential misconceptions that can arise about the use of AI in drug discovery process and how it can be resolved over time.
#drugdiscovery #aiindrugdiscovery

Are AI-Developed Drugs From Wealthy Nations Accessible in Lower-Income Countries? Artificial intelligence (AI) is rapidly transforming healthcare, from diagnosing diseases to discovering life-saving medications. Yet, understanding the role of AI in such a complex and evolving field can be challenging. Misinformation, technical jargon, and gaps in accessibility often leave us with more questions than answers. That’s why we’re here—to address your questions with factual, up-to-date, well-researched, and actionable information. In this series, we tackle the critical and nuanced topics shaping healthcare, ensuring you have the clarity and insights to navigate this AI-driven era confidently. Question from our readers: Are AI-Developed Drugs From Wealthy Nations Accessible in Lower-Income Countries?

Ensuring equitable access to AI-developed drugs in low- and middle-income countries (LMICs) remains a complex challenge. Recent developments highlight both progress and ongoing obstacles. #AIinDrugDiscovery

AI-Designed Drug Receives FDA Clearance for Cancer Clinical Trials The future of medicine is here, and artificial intelligence (AI) is leading the charge. In a significant development, Insilico Medicine, a biotechnology company at the forefront of AI-powered drug discovery, announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for ISM5939. This AI-designed drug is set to enter clinical trials for the treatment of solid tumors, marking a pivotal moment in the fight against cancer. What Makes ISM5939 Unique? ISM5939 is no ordinary drug. It targets an enzyme called ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which plays a critical role in the progression of certain cancers.

Its unique mechanism of action, targeting ENPP1 to boost the immune response, represents a novel approach that could complement existing therapies like chemotherapy and immunotherapy. #InsilicoMedicine #AIinDrugDiscovery